This study provides critical clinical evidence for a time-limited immunotherapy strategy in advanced clear cell renal cell carcinoma (ccRCC), suggesting that pembrolizumab combined with high-dose IL-2 can achieve durable disease control, offering important directions for optimizing patient treatment pathways and subsequent biomarker research.
Literature Overview
The article titled “Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial,” published in Nature Communications, systematically investigates the long-term efficacy and safety of pembrolizumab combined with high-dose IL-2 in treatment-naïve patients with advanced clear cell renal cell carcinoma (ccRCC), and integrates multi-omics analyses to uncover immune molecular features associated with durable responses. With a median follow-up of 76.4 months, the study provides key data on overall survival, progression-free survival, and treatment-free intervals for this combination regimen, while deeply analyzing the immune microenvironment characteristics of extreme responders.Background Knowledge
Advanced clear cell renal cell carcinoma (ccRCC) is a highly immunogenic tumor, and its treatment has long relied on combinations of targeted therapy and immune checkpoint inhibitors (ICIs). However, most current regimens require prolonged or even indefinite treatment, leading to cumulative toxicity, economic burden, and reduced quality of life. Although dual immunotherapy regimens such as nivolumab + ipilimumab have significantly improved overall survival (OS), only about 18% of patients remain off subsequent therapy at 5 years, highlighting the urgent need for curative, finite-duration treatment strategies. PD-1 inhibitors enhance anti-tumor immunity by blocking T-cell exhaustion signals, while IL-2 promotes the proliferation and activation of T cells and NK cells, making their mechanisms complementary. However, traditional high-dose IL-2 monotherapy has been limited by severe toxicity, and the recent BEMPEG (an IL-2 prodrug) combined with nivolumab failed to outperform TKIs, suggesting that strategies for IL-2 pathway activation require optimization. This study’s innovation lies in using a sequential rather than concurrent administration of pembrolizumab and high-dose IL-2, aiming to “prime” the immune system via PD-1 blockade and subsequently “amplify” the response with IL-2 to achieve deep and durable responses, while also exploring predictive biomarkers to guide patient selection.
Research Methods and Experiments
This was a single-arm, single-center phase 2 clinical trial (NCT02964078), enrolling 26 treatment-naïve patients with advanced ccRCC who received a fixed-cycle regimen of pembrolizumab combined with high-dose IL-2. The treatment plan consisted of multiple phases: initial pembrolizumab monotherapy, followed by combination with IL-2, and then pembrolizumab maintenance until completion of 12 doses or disease progression. Primary endpoints were safety and objective response rate (ORR), with key secondary endpoints including overall survival (OS), progression-free survival (PFS), treatment-free interval (TFI), and biomarker analysis. Efficacy was assessed using RECIST 1.1 criteria, and peripheral blood samples collected at multiple time points were analyzed via transcriptomics (NanoString), proteomics (Olink), and flow cytometry to explore immune dynamics associated with treatment response. This design allowed evaluation of long-term outcomes under a finite treatment strategy in real-world conditions, while longitudinal sampling enabled tracking of immune remodeling.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents a potential finite-duration immunotherapy strategy for advanced ccRCC that may lead to “functional cure,” challenging the current paradigm of long-term treatment. Its high CR rate and extended TFI suggest that some patients may achieve durable immune memory, reducing the burden of prolonged therapy. From a research perspective, features such as CD16+ NK cell expansion and reduced PD-1+ T cell frequency provide directions for developing predictive biomarkers, which can be validated in larger cohorts. Furthermore, the identified activation of chemokine and TGF-β pathways suggests these may serve as intervention targets to enhance therapeutic efficacy. These findings support future randomized controlled trials comparing this combination with standard first-line therapies, and exploration of its application in other immunogenic tumors.
Conclusion
This study establishes pembrolizumab combined with high-dose IL-2 as an effective and safe finite-duration treatment strategy for advanced renal cell carcinoma, with six-year follow-up data showing high complete response rates and extended treatment-free intervals, suggesting that some patients may achieve long-term disease control or even “functional cure.” These results not only offer patients a new option to reduce treatment burden but also reinvigorate exploration of IL-2’s role in modern immunotherapy. Through multi-omics analyses, the study identifies immune features associated with durable responses, such as CD16+ NK cell expansion and reduced PD-1+ T cell frequency, laying a solid foundation for future biomarker development and mechanistic research. From bench to bedside, this study highlights the potential of integrating immune checkpoint inhibition with cytokine therapy and provides a blueprint for designing more precise, individualized finite-duration immunotherapies. Future validation in larger studies is needed, along with exploration of how these biomarkers can inform clinical decisions to optimize care for advanced ccRCC, enabling a shift from “chronic control” to “deep remission.”
